Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes

Nicoletta Adamo (Lead / Corresponding author), Sarah Seth, David Coghill

    Research output: Contribution to journalArticlepeer-review

    24 Citations (Scopus)


    A substantial body of evidence has supported the efficacy and safety of pharmacological treatment available for attention deficit/hyperactivity disorder (ADHD). There is increasing agreement that the important treatment outcomes for ADHD extend beyond improvement in core symptoms and that a more generic (or global) concept of remission is the overarching goal of treatment. However, there is no consensus on the best definition of remission or on how best to conceptualize and measure broader treatment outcomes. In this article, we provide an overview of the various methods and approaches to measuring treatment outcomes for ADHD with respect to symptoms, impairment, quality of life, adverse events and safety as well as cognition. We will describe the ways that they may be used within routine clinical practice and think ahead about the kinds of studies that are required to move the field forward.

    Original languageEnglish
    Pages (from-to)383-397
    Number of pages15
    JournalExpert Review of Clinical Pharmacology
    Issue number4
    Publication statusPublished - Jul 2015


    • ADHD
    • Adverse events
    • Cognition
    • Functional impairment
    • Quality of life

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology, Toxicology and Pharmaceutics(all)


    Dive into the research topics of 'Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes'. Together they form a unique fingerprint.

    Cite this